The Lancet· Marc A Riedl, Philip H Li, Adil Adatia, Mauro Cancian, Marcin Stobiecki, Anna Valerieva, Anete S Grumach, William R Lumry, Daniel F Soteres, Nicholas Brodszki, Natalia L Fili, Roman Hakl, Hye-Ryun Kang, Gul Karakaya, Birger Kränke, H Henry Li, Jonny Peter, Andreas Recke, Raffi Tachdjian, Paola Triggianese, Andrea Zanichelli, John Anderson, Emel Aygören-Pürsün, Timothy J Craig, Henriette Farkas, Francesco Giardino, Pedro Giavina-Bianchi, Sujeong Kim, Tamar Kinaciyan, Inmaculada Martinez-Saguer, Francesca Perego, Karl V Sitz, Maria Staevska, H James Wedner, Rafael H Zaragoza-Urdaz, Ricardo D Zwiener, Asli Gelincik, Francesco Arcoleo, Rand Arnaout, Alan P Baptist, Régis de Albuquerque Campos, Anthony D Dorr, Mariana Paes Leme Ferriani, Atsushi Fukunaga, Delphine Gobert, Padmalal Gurugama, Michihiro Hide, David I Hong, Eisuke Inage, Joshua S Jacobs, Constance H Katelaris, Lucy Leeman, Ramón Lleonart, Markus Magerl, Michael E Manning, Satoshi Mano, Seido Ooka, Cristina J Ramos, Jinzhong Liu, Li Zhu, Joan Mendivil, Umar Katbeh, Giorgio Giannattasio, Rafael Crabbé, Ming Yu, Anne Lesage, Peng Lu, Danny M Cohn·· 2026-10-09精选AI 评分72
口服deucrictibant治疗遗传性血管性水肿发作的III期试验显示症状缓解快于安慰剂
[Articles] Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial
AI 导读
一项III期、多中心、随机、双盲、安慰剂对照交叉试验显示,口服deucrictibant治疗遗传性血管性水肿发作时,症状缓解时间快于安慰剂,且总体耐受性良好。作者认为,这些结果支持deucrictibant成为潜在首个口服缓激肽B2受体拮抗剂,用于治疗缓激肽介导的血管性水肿发作(包括遗传性血管性水肿),并可能满足对有效、耐受良好且给药便捷的治疗选择的需求。
推荐理由
III期试验显示口服deucrictibant较安慰剂更快缓解遗传性血管性水肿症状,为口服按需治疗提供依据。
来源:The Lancet · thelancet.com